A new amoxicillin/clavulanate therapeutic system: Preparation, in vitro and pharmacokinetic evaluation

Kerč, Janez; Opara, Jerneja

doi:10.1016/j.ijpharm.2006.11.007

Cited by 16 publications

(12 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Tsou et al (1997) and Kerč and Opara (2007) established high-performance liquid chromatography (HPLC) with ultraviolet (UV) methods for simultaneous determining AMX and CLV in pharmaceutical preparations, respectively. Hoizey et al (2002) and Foroutan et al (2007) developed HPLC-UV methods for determining AMX and CLV in plasma, respectively.…”

Section: Introductionmentioning

confidence: 99%

Simultaneous Determination of Amoxicillin and Clavulanic Acid in Dog Plasma by High-Performance Liquid Chromatography Tandem Mass Spectrometry

Guo

et al. 2012

Analytical Letters

View full text Add to dashboard Cite

A rapid, sensitive, and specific high-performance liquid chromatography tandem mass spectrometric method was developed for the simultaneous determination and confirmation of amoxicillin and clavulanic acid in plasma. Plasma sample was subjected to a simple deproteinization with acetonitrile, and then the supernatant was directly diluted by water. Analysis was performed on a Phenomenex Luna C 8 reversed-phase column by detection with mass spectrometry in negative ions multiple reaction monitoring mode. A gradient elution program with 0.1% formic acid and acetonitrile was performed at a flow of 0.25 mL min À1 . There is good linearity in the range of 0.5-500 ng mL À1 for both amoxicillin and clavulanic acid. The decision limits of amoxicillin and clavulanic acid were 0.06 ng mL À1 and 0.08 ng mL À1 in plasma, respectively, and the detection capabilities of two analytes were below 0.5 ng mL À1 . Acceptable precision and accuracy were obtained for concentrations over the standard curve range. The extraction recoveries of amoxicillin and clavulanic acid were between 102% and 115% in plasma at three spiked levels of 0.5, 50, and 500 ng mL À1 , with the relative standard deviations less than 15% for each analyte. The developed method was applied to pharmacokinetic studies of amoxicillin and clavulanic acid tablets in healthy beagles.

show abstract

Section: Introductionmentioning

confidence: 99%

Simultaneous Determination of Amoxicillin and Clavulanic Acid in Dog Plasma by High-Performance Liquid Chromatography Tandem Mass Spectrometry

Guo

et al. 2012

Analytical Letters

View full text Add to dashboard Cite

show abstract

“…Higuchi's square root of time Ali et al (2007) [93] Metformin Capsule Low density Zero order Ishak et al (2007) [101] Metronidazole Alginate beads Low density Zero-order Chavanpatil et al (2006) [97] Ofloxacin Tablets Swelling and channeling agent Higuchi Kerc and Opara (2007) [102] Amoxicillin/Clavulanate Capsule Hollow core…”

Section: Gas Formationmentioning

confidence: 99%

Drug release kinetics and physicochemical characteristics of floating drug delivery systems

Adibkia

Hamedeyazdan

Javadzadeh

2011

Expert Opinion on Drug Delivery

View full text Add to dashboard Cite

Developing an efficient floating dosage form is reliant on a better understanding of the relation between formulation variables and performance of the floating systems. Generally, the combination of two buoyancy mechanisms and gas-generating systems with swellable polymers would be beneficial for obtaining an appropriate floating lag time and duration of buoyancy, which in turn guarantees optimum efficiency of the pharmaceutical dosage form.

show abstract

“…The generated gas is trapped and protected within the gel formed by hydration of polymer, thus decreasing the density of the tablet. As the density of the tablet falls below 1 g/cm 3 , the tablet becomes buoyant (2). All the prepared trimetazidine floating tablets showed an acceptable weight variation range from 198 to 203 mg with standard deviation <2%, and not more than two tablets were allowed to deviate from the average by more than twice the previous percentage (30).…”

Section: Fabrication and In Vitro Characterization Of Trimetazidine Dmentioning

confidence: 99%

“…The generated carbon dioxide was trapped and protected within the gel formed by hydration of polymer, thus decreasing the density of the tablet. As the density of the tablet falls below 1 g/cm 3 , the tablet became buoyant. All tablet formulas showed a floating lag time of <0.5 min (SD<0.01), good matrix integrity, and floating duration of more than 12 h.…”

Section: Floating Lag Time and Floating Duration Of The Tabletsmentioning

confidence: 99%

“…Gastroretentive systems can remain in the gastric region for several hours and hence significantly prolong the gastric residence time of drugs and produce retardation in drug release. Gastric retention helps provide better availability of new products with new therapeutic possibilities and substantial benefits for patients (2,3). The controlled gastric retention of solid dosage forms may be achieved by the mechanisms of mucoadhesion (4,5), flotation (6), sedimentation (7,8), expansion (9,10), modified shape systems (11,12), or by the simultaneous administration of pharmacological agents that delay gastric emptying (13)(14)(15)(16).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Floating Tablet of Trimetazidine Dihydrochloride: An Approach for Extended Release with Zero-Order Kinetics

et al. 2010

View full text Add to dashboard Cite

Abstract. Trimetazidine dihydrochloride is an effective anti-anginal agent; however, it is freely soluble in water and suffers from a relatively short half-life. To solve this encumbrance, it is a prospective candidate for fabricating trimetazidine extended-release formulations. Trimetazidine extended-release floating tablets were prepared using different hydrophilic matrix forming polymers including HPMC 4000 cps, carbopol 971P, polycarbophil, and guar gum. The tablets were fabricated by dry coating technique. In vitro evaluation of the prepared tablets was performed by the determination of the hardness, friability, content uniformity, and weight variation. The floating lag time and floating duration were also evaluated. Release profile of the prepared tablets was performed and analyzed. Furthermore, a stability study of the floating tablets was carried out at three different temperatures over 12 weeks. Finally, in vivo bioavailability study was done on human volunteers. All tablet formulas achieved <0.5 min of floating lag time, more than 12 h of floating duration, and extended t 1/2 . The drug release in all formulas followed zero-order kinetics. T4 and T8 tablets contained the least polymer concentration and complied with the dissolution requirements for controlled-release dosage forms. These two formulas were selected for further stability studies. T8 exhibited longer expiration date and was chosen for in vivo studies. T8 floating tablets showed an improvement in the drug bioavailability compared to immediate-release tablets (Vastrel® 20 mg).

show abstract

A new amoxicillin/clavulanate therapeutic system: Preparation, in vitro and pharmacokinetic evaluation

Cited by 16 publications

References 33 publications

Simultaneous Determination of Amoxicillin and Clavulanic Acid in Dog Plasma by High-Performance Liquid Chromatography Tandem Mass Spectrometry

Simultaneous Determination of Amoxicillin and Clavulanic Acid in Dog Plasma by High-Performance Liquid Chromatography Tandem Mass Spectrometry

Drug release kinetics and physicochemical characteristics of floating drug delivery systems

Floating Tablet of Trimetazidine Dihydrochloride: An Approach for Extended Release with Zero-Order Kinetics

Contact Info

Product

Resources

About